Good day, and thank you for standing by. Welcome to the third quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your speaker today, Linda Moore, Chief Legal Officer. Please go ahead, ma'am. Good afternoon, everyone, and thank you for joining our call. Welcome to the 2021 third quarter earnings conference call for Marrone Bio Innovations. Our presenters today are CEO Kevin Helash and CFO Sue Cheung. During the Q&A section, we will be joined by Matti Tiainen, our Senior Vice President of International Sales. If you would please refer to slide two. I would like to remind you that this conference call may contain forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding management's future expectations, plans, projections, forecasts, and prospects. Certain material assumptions were applied in reaching these conclusions and making these statements. Therefore, actual results could differ materially from those contained in our forward-looking information. Important factors that could cause differences are contained in the reports filed by the company with the Securities and Exchange Commission, including under the heading Risk Factors, MD&A, and elsewhere in the company's annual report, quarterly report, and other filings. The company expressly disclaims any obligation to revise or update any guidance or other forward-looking statements to reflect events or circumstances that may arise after the date of this call. After our remarks, we will hold a question-and-answer session. I will now turn the call over to our CEO, Kevin Helash. Kevin? Thank you, Linda. Thanks to everyone joining us on the call today. If you would turn to slide three. As COVID restrictions have eased over the past several months, I've been fortunate enough to attend multiple meetings and events with key customers and industry peers. In our business, weather is always a topic of keen interest, and the recent wet weather in California and the Pacific Northwest was certainly welcomed and is a great start to what we hope will be a normal winter in terms of precipitation in the Western United States. What is different this year, however, is a hyper-focus on rising expenses for seed, fuel, fertilizers, and crop protection products. As just two examples, the price of North American fertilizer set another record late last week, and top producers are signaling that prices will continue to climb. There are also widespread shortages of key herbicides, the costs of which have also ballooned. Inventories are so tight that even growers who are fortunate enough to have storage space on farm and the cash on hand to pay up front may not be able to lock in their supply of certain inputs. Everyone is experiencing supply chain challenges, from basic raw materials to ocean containers, and by all accounts, we will have to manage our way through this situation well into next year. The positive side of the story is commodity prices. Corn and soybeans hit an eight year high this spring, and while they have moderated somewhat, current projections are for higher net farm income in 2021, which will bode well for crop input demand in 2022. All of these factors play into a level of uncertainty as to which products distributors and growers will buy and when. The Latin American growing season is underway, and after a year of severe drought, the main growing areas of Brazil have received abundant rainfall, leading to revised forecasts of record planting intentions for both corn and soybeans. The Southern Hemisphere harvest, in turn, will affect commodity prices and planting intentions in the Northern Hemisphere this spring. In this environment, our greatest strength has been our decision to diversify. We have the product line and, equally important, the distribution channel that will allow us to win, whether the farmer chooses corn or soybeans. We can succeed in specialty crops as well as the large row crop market. We can serve a farmer in Europe as easily as one in Argentina, and we can protect a crop from seed to leaf. In times of uncertainty, optionality like ours is a powerful tool. If you would turn to slide four, let me expand on how I see us positioned for the remainder of the year and into 2022. Sue will go into the third quarter financials in a moment, but my key takeaways are this. First, our team has been remarkably resilient during this period, and their dedication towards supporting our customers continues to impress me. Second, the strength of our portfolio remains a strategic advantage and has allowed us to grow sales in the double digits despite the headwinds we've experienced. Third, access to the market through our channel partners provides us with outstanding opportunities to creatively position our products in all sectors as we move into the 2022 crop year. That being said, we are cautiously optimistic about successfully closing out the year. Given current market dynamics, it is fair to assume there will be greater variability between the fourth and first quarters and therefore prudent to widen the band of expected revenue growth, which we now anticipate will be in the low double digit to mid-teens range for 2021. At roughly the midpoint of the fourth quarter, we have already booked or have purchase orders in-hand for half of our targeted revenues for this period. There is still plenty of heavy lifting to be done, but this is solid progress. We continue to expect our product mix will deliver annual gross margins in the upper 50% range and operating expenses should remain in line with 2020 plus inflation. As we prepare for more robust sales in 2022, we must execute on some key tactics. First, we must stay ahead of the supply chain to ensure raw materials are in place to manufacture our products without disruption. You'll see this reflected in our balance sheet this quarter as we are strategically building inventories in anticipation of sales needs in 2022. We believe our manufacturing position in the United States is a competitive advantage in this environment, as many of the alternatives are coming to the U.S. from overseas with greater delivery risk. We intend to be the first in line to supply our biological solutions in season to fill potential gaps in the delivery of traditional products, many of which are in short supply. Second, we have to be in close concert with our customers to anticipate grower demand during this dynamic environment. We need to have the right product with the right value proposition in the channel well ahead of time to ensure availability to maximize sales. Third, the value of our seed treatment business has never been greater. Growers may pull back on fertilizers and crop protection products in tough times, but if they're going to grow a crop, they have to plant seed. Our products are applied by our seed company channel partners, so it's a near guarantee that when a grower purchases a bag of corn, soybeans, or cotton from one of our seed partners, we're there. Fourth, we need to exploit the advantages of our BioUnite program, as shown on slide five. Our prescribed tank mixes have the opportunity to grow dramatically in a time of tight supply and accelerating costs. We believe this can open new doors for us to demonstrate the tremendous benefits our products offer. This is a unique point in time to promote our BioUnite offerings, allowing growers to stretch their dollars by using cost-effective and sustainable products with the traditional active ingredients. Strategically, our plan has been validated this year, even as we dealt with external challenges on the revenue front. The macro trend toward growing food with a gentler footprint that preserves natural resources and slows climate change has not changed. MBI has been and continues to be at the cutting edge of meeting this need, and the value of our products is being borne out in this environment. We can't rest on our current portfolio or market reach to succeed. As you see on slide six, further diversification is critical to accelerating our growth. We've made great strides with a broader portfolio to expand our presence into a wider market, and we intend to maximize these opportunities. At the same time, we are still aggressively pursuing strategic alternatives to expand our capabilities in our core business that support the build-out of our leadership in sustainable agriculture. While it is always challenging to find the right opportunity, I'm confident we will. At the same time, we are pushing hard on a refocused R&D pipeline. The recent regulatory submissions for our novel insecticides and nematicides, MBI-306 in the United States and MBI-206 in Brazil, are major milestones for us. Late-stage developments in our herbicide program are giving us three different products to tap into a $27 billion market that is void of new, efficacious, and cost-effective solutions. Even with these advancements, we can't rest on our laurels. We're also exploring opportunities that will complement and turbocharge our R&D power to ensure we are employing the latest and greatest tools to ensure our long-term success. Having spent most of my career in the distribution side of agriculture, I'm very pleased with the breadth and depth of our distribution network. We're working with the right partners and have reached into all major markets, particularly for row crops. I'm also confident in our manufacturing capabilities. Our decision to invest in our Michigan manufacturing plant looked good when we made it last year, and it looks even smarter in today's environment. Strategically, we are well-positioned to regain our momentum and position our products for the upcoming 2022 season. Of all our capabilities, I'm most confident in the commitment and drive of our team to rebound from the challenges of 2021 and deliver on the full potential we offer to change the way food is grown to the benefit of our customers, our shareholders, and our environment. I'd like to turn the call over to Sue now to go further into the financial results for the quarter and year-to-date. Sue? Thank you, Kevin, and good afternoon to everyone on the call. If you will turn to slide seven, revenues grew 12% to $9.9 million in the third quarter, driven by higher sales of seed treatments and fungicides. Our strategic shifting to more global markets with our high-value seed treatments was reflected in our gross profit for both the quarter and for the first nine months. In third quarter, gross profit rose 21% to $6 million, and gross margins were 61.4%. Year-to-date, gross profit was up 16%, and gross margins were 62.1%. We're committed to managing our costs effectively and have a target of keeping operating expenses at the same level in 2020 plus inflation. We achieved this again in the third quarter with operating expenses of $10.5 million, essentially flat on a year-over-year basis. For the first nine months of the year, revenues were outpacing operating expenses. As a result, our operating expense ratio decreased to 91% as compared to 101% in the same period of 2020. On a comparative basis, I want to remind you that 2020 operating expenses had a one-time benefit of $1.4 million from the PPP loan. As we continue to scale our business internationally, it's important that we have the right systems in place to support our growth. We're investing in automating some back-office processes that will allow us to scale without increasing headcount. This is another example of our commitment to both growth and operational efficiencies. The combination of higher revenues and gross margins, coupled with cost management, have improved our bottom-line results. Our net loss for the third quarter decreased by 18% with a loss of $4.9 million in 2021, as compared with a loss of $6.1 million in the third quarter last year. For the first nine months of 2021, the net loss was $11.2 million, as compared with a net loss of $16 million in the same period last year. We continue to improve adjusted EBITDA with a 22% improvement for the third quarter and a 47% improvement for the year-to-date. Continued reduction of the net loss and efficient working capital management have improved our cash flow from operations. The use of cash from operations decreased 64% for the third quarter and 24% for the year-to-date. In summary, our continued expansion into new markets has allowed us to grow revenues and improve our product mix in the face of external challenges. Coupled with effective cost management, we're continuing to move toward our goal of achieving positive adjusted EBITDA. With that said, I'd like to now turn the call back to Kevin for his closing remarks. Kevin? Thank you, Sue. As we complete this year, we are mindful of both the unique challenges before us and the opportunities they present. We continue to believe that Marrone Bio is uniquely positioned to capitalize upon the growing desire by stakeholders around the world to produce safe, healthy, affordable food with a gentler footprint, and the execution of our strategy will ensure we maintain our leadership position in the sector. With that being said, I'd like to turn the call over to the operator for your questions. Operator? Thank you, sir. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your questions, you may press the pound key. Please stand by while we compile the Q&A roster. Speakers, we have our first question from Gerry Sweeney of Roth Capital. You may ask your question. Good afternoon, Kevin and Sue. Thanks for taking my call. A question. Hey, Gerry. Hey, Gerry. You know, I wanted to start with just with the supply chain. Obviously, we're hearing lots about it. Curious if this is more an issue of Marrone maybe acquiring raw materials to produce or is this more of an issue getting product out to through your distribution channel? If it's hitting any one particular products in particular, or is it spread across the entire portfolio? Yeah, Gerry, great question. I mean, there's been a lot of talk about supply chain in the news everywhere, no matter if you're in Europe or South America, North America. From our standpoint, Gerry, it's a little bit all over. If you think about the inbound, the manufacturing, and the outbound to our customer, I would say that our supply chain team has done an absolutely fantastic job in managing the situation. We've significantly expanded our vendor list to supply everything from sweeteners to tote lids to pallets. In terms of outbound, Gerry, we're continuously looking for new transportation logistics partners as well to ensure we're able to get wheels under our products and get them delivered to farm. The short answer to your question is, it's a little bit on the inside, in the inbound, and it's a little bit on the outbound, but again, we feel that we're managing the situation quite well, you know, in spite of you know everything going on around us. Got it. The follow-up to that would be obviously, you know, disruptive conditions here, but sometimes there's opportunity. I think you touched upon it in your remarks just about, you know, agricultural commodity or, chemicals across the board and inputs are stressed. Is this an opportunity for you to get some of your products into the market a little sooner? Maybe people adopt the products a little faster or people that normally hadn't planned on using some biologicals moving into that market and drive a faster adoption rate. Have you seen any inkling or, you know, sense of that? Jerry, that's a great question. You know, we certainly do see this as an opportunity. There is a lot of worry in the marketplace about getting the traditional products on farm, you know, on time, or getting them at all. Certainly by us having our manufacturing facility in Michigan and, in Europe, you know, we're close to the market. We've got competitively priced products, and it's a great opportunity, as we mentioned, for our BioUnite strategy to be deployed, whereby we can increase our participation in a grower's program and not only provide them with great products, but also help them extend the acres that they can cover with their traditional chemistry or traditional crop protection products. We're certainly looking at it as an opportunity, and as I mentioned in my opening remarks, it will be an area of focus for us going into 2022 and beyond. Okay, great. I'll jump back on then. I appreciate it. Thank you. Thanks, Gerry. Our next question from Laurence Alexander of Jefferies. You may ask your question. Hi, Laurence. Hi there. Can you help on two thing fronts? One, in terms of the international expansion, can you give any detail on geographies or product categories where you're seeing demand pull, or particular traction? How much of this is cross-selling the same applications to, you know, where you validate them in the U.S. to the same crops, or you're going into different crops, you know, and show, you know, proving different market relevance, if you see what I mean. Then the second one is any kind of field trials or key data out of the most recent season that would have materially changed how you look at the ranking of the products in your R&D pipeline. Great. Thanks, Laurence. Good to hear from you again. I have Matti on the phone with me, our Senior Vice President of international. I'll turn the question over to him in a minute. In terms of the question, you know, where are we expanding geographically? Our core markets continue to be North America, Europe, and Latin America. Not to say that we're not doing work in others. I would call those our core. I'll let Matti talk about you know, how things are going in those markets in a second. In terms of, you ask a great question about are we able to leverage our knowledge and experience from our field trials in the markets that we're currently in to move outside. The knowledge that we've gained in Europe, the knowledge that we've gained in North America, can we deploy that into Latin America? The short answer is yes. Certainly, we're going into those markets, a new market with a significant amount of knowledge in terms of how our products work, what crops they work on, what type of an application protocol should you have. It really is a tremendous benefit for us to help fast-forward our commercialization of our products. It certainly helps with the registration from a registration standpoint, setting up our field trials and then demonstrating the effectiveness of our products. In terms of answering your last question, have we seen anything in our field trial data that's changing our ranking? I would say actually, Laurence, the opposite. By what we've seen this year, it is convincing us even more that we're on the right path. We've got fantastic products. They're absolutely doing amazing, showing amazing performance in the field. It's not only impressing us when we're sharing the data with our channel partners, it's really getting them excited, you know, especially when we're talking about our 306 programs and even some early-stage work on our herbicides. Matti, I'll kick it over to you for any additional thoughts. Yeah. Thanks, Kevin. I think you covered well the ranking part. I agree that there, in terms of prioritization of the pipeline and what we're seeing in the trials, I agree it's really, you know, 306 and the early, you know, signs we're seeing from the herbicide program definitely keeps the whole channel and our partners awake and excited about what's to come. At the same time, I think, you know, what's really great, specifically on the international expansion, when we look at our biopesticide portfolio, we really see, you know, us covering the ground with the local pests and diseases. We're really getting, you know, hitting the mark with our data locally as well, because that's always the case that you have to build the case locally and then prove the efficacy and that's what we've been able to do. Even in some cases, to the extent that we're extremely competitive from all points of view in the local market. That, you know, it's not a surprise per se, but it's something that we were really expecting. Once we've now delivered that data and submitted, for example, MBI-206 dossier here in Brazil now, which we expect the registration for the latter part of 2023, I think that's gonna be an exciting one, definitely. In Europe, we're building up also with the upcoming submissions. Thanks for the first question as well. I think, you know, I'm just trying to break it down to try to make it short and sweet because there were so many good aspects, and it's really touching the point of our international expansion and the breakthrough moment that we're having there. Geographically, as Kevin mentioned, we're really, you know, looking at North America, but then internationally we're focused on Europe and South America, as well as parts of Africa. What we're seeing today is, you know, first we've covered ground on the seed treatment part. We're already on over 25 million acres. Starting from next year, we're seeing a new ground where we're actually starting to dominate the seed space, so we're having more than one product on the same seed. This is our promise to deliver more and more value to the seed and all the way to the growers so we can really develop technologies that complement each other and bring value to the channel. I think that's an exciting benchmark that we're having more than one product on the seed going into the market. Now in terms of crops and products, if I'm you know now keeping up with your segmentation from the great question, we launched three new products this year in Europe alone, and these were in the plant health and biostimulant sector. That answers also to the other question. The pool that we see is equal. There's a great need for biopesticide, be it Europe or South America or Africa. You know, the regulatory timelines that we've been working through diligently, and we have a great regulatory department working on these details, but it's still gonna take a bit more longer time than it does with plant health and biostimulants. What we have to offer as a company is really something valuable from the plant health and biostimulants perspective to really address the market, and then build on our portfolio also in the future pipeline by bringing those biopesticides. Again, taking one step back. On the crop side, we've been working a lot with corn. On seed treatment, we've been working with corn, sunflower, oilseed, grape, soybean, but also we've broken through into the cereals market in Europe this year with the launch of Ympact product, a downstream cereal seed treatment product in Europe that we also expect to roll over to North American markets and also South American markets. On top of that, we have two premium product launches this year, mainly targeted for corn, that we also expect to carry a you know great performance and also great value throughout the whole channel. On top of this, looking at the pipeline from our biopesticide portfolio underneath, you know, Europe and South America are the leading CAGR growers in biologicals, right? We have a great pipeline on the regulatory side in submissions and also then in partners that we've selected for these products and then go-to-market plans. So our medium and long-term plans are really well covered from these launches. So all in all, it's a really well-balanced mix, both short, medium, and long term. There is great pull, and we can offer something in the short term, medium term, and long term. But if I would have to highlight something from, you know, from this quarter is we launched a new seed treatment product with Rizobacter in Argentina. In the plant health and biostimulant side, we launched a new cereal seed treatment product in Europe, that's also gonna cross over to North America, which is by far the largest seeded crop. We have these premium product launches also on the seed treatment side. I think we're pretty well laid out for the breakthrough here. Could you help me with just one. I don't know if there's a simple way to characterize this. You know, if you think about sort of the applications you have in your R&D pipeline and the potential acre touches, if you had a customer who woke up one day and just decided they absolutely loved your entire portfolio and used everything to the maximum of its potential, what would be kind of the revenue per acre? Or kind of, you know, how can we think about what the revenue opportunity might be at a farmer who just thinks your portfolio is the cat's meow? Yeah. Laurence, that's a very interesting question. Not to be evasive, but I will say that it depends on the crop. If we're looking at high-end specialty, where you do multiple sprays during a season versus, let's say, you know, Matti was talking about wheat or cereals as an example, it will be quite different. You know, it's a question that we'll dig into a bit more and come back to you on. You know, I think if I think about what percentage of the acres we're on today, even with the growers that are with us, you know, in terms of what the potential is, we're not even scratching the surface, Laurence, right? That's a good question. We'll come back on that one too and give you a better answer. Okay. Thank you. Yeah. To further add, I'll just add to Kevin's point one, that I think that our BioUnite strategy as well is, you know, exactly to Kevin's point. We're scratching the surface. I think that's the vehicle that is also taking us towards the bigger budget when the grower is thinking and allocating the resources in terms of what the inputs are. BioUnite and the performance of our products really puts them outside of that, you know, biological budget or that specialty budget that growers used to have and puts us into the main budget. I think that not only are we scratching the surface, but we're also we have the ability to be allocated to the main budget, if you may, from a grower standpoint. Right. Making yourselves easier to buy or do business with. Got it. Right. Okay. Thank you. Thanks. Thanks, Laurence. Our next question is from Ben Klieve of Lake Street Capital Markets. You may ask your question. Hey, Ben. All right. Hey, good afternoon, Kevin. Thanks for taking my questions. I got a couple on the quarter and then one on the R&D side. First on the quarter and kind of the conditions you guys are facing now, particularly around the drought. My first question is, you know, the second quarter headlines that you saw that were drought related. Did you see any of the kinda lost business in the quarter get pushed into the third quarter or maybe into the fourth quarter that's yet to be realized? Is the business that you know really just wasn't able to be realized because of the drought proven to be gone? Yeah, Ben, you know, the way we think about it or the way it works is that you only have that one time to spray that acre, right? I mean, if you lose a spray, let's just say, for example, in an orchard, you're gonna spray it two, three, four times. If you miss one of those sprays, they won't make it up later, right? When it's gone, it's gone. You know, we still have a very resilient business. I mean, you know, we're looking at our order book and the enthusiasm of our customers and, you know, they're already planning for 2022. You know, they're talking to us about how do we load up the channel to ensure we've got the product in place, and making sure that we've got programs that meet the needs of the growers to ensure, you know, they are also participating all the way through, you know, from now until when they need the product. Yeah, we can't go back and respray that acre, Ben, to answer your question, but certainly the mindset today is, you know, the spring of 2021 is behind us, and we're looking forward to 2022. Gotcha. That leads into my next question is, let's say that drought conditions continue into next year. What, if anything, are you guys doing internally here to kind of prepare for, you know, for repeat conditions, if anything can be done? Well, certainly, Ben, we're starting with planning for what we consider to be a normal season, right? We're planning for success. We're getting our product positioned. We're working with our customers, as I mentioned, on marketing programs. We are putting a lot more horsepower this year into our BioUnite program to ensure that people understand how a biological can fit into a standard practice, whether you're an organic farmer, obviously, who is using our products today, but a conventional farmer. How does it work? How would you employ a product like ours into your program? Then in terms of, you know, just dampening the impact of any specific weather event, whether it's in North America, Europe or Latin America, you know, we continue to expand our portfolio in terms of our product line. We're expanding our footprint in terms of the markets we're serving, and we're expanding our product portfolio as we mentioned, and specifically in seed treatment. You know, we're not trying. We are expanding the footprint and the diversity of this company so that we're not heavily reliant upon one particular market for a major amount of our success going forward. Got it. Very helpful. Yeah, you've been doing that for a while, and it's a great success. Wish you continued success on that front. May the wet conditions that have been seen by you guys over the last couple weeks out there continue here in the next year. Another question on the R&D side. You know, talked a lot about this already, but I'd like to maybe dive into the herbicide portfolio that you have. 'Cause I mean, the bio-herbicide seems to be the holy grail in the biological space. I'm curious kinda what needs to happen for those, I believe, three different products between now and commercialization. You know, you've referred to kind of formulation improvement, but, you know, really wondering kinda what steps need to take place before you believe you're gonna be able to bring those products to market. Great question, Ben. You know, I can say that everybody in this company is extremely excited about our herbicide platform. You're right, we have three. We have two that are post-emergent, and we have one that is pre- and post-emergent which we believe is a very unique product that has both characteristics that you can apply it before the weeds show up and also after the weeds are growing in the field. In terms of what do we need to do, there's always work here, Ben, in terms of improving our formulation and increasing the concentration. Two of them we are, I'd say, very close to getting it to a point where we believe we can have our first commercial launch. It may not be at the final endpoint where we can say, "Look, we're gonna go from everything from almonds and strawberries all the way to wheat." Certainly getting a product out there that does fit in some of the higher-end markets, broader, I mean, bigger, higher end markets, we think we're making great strides. I'd say, you know, as we continue to work with these products and put more of our attention on there, work with some of our collaboration partners on the chemistry and the formulation, yeah, we'd say we have a clear line of sight to getting these products to market. These aren't a pipe dream, and they're not, you know, far back in the R&D shop. These are active and real, and we're getting very encouraging results out of the lab and in some of our real world trials as well. Perfect. If you don't mind, a follow-up to that. Can you elaborate kind of on where, you know, that portfolio stands in terms of field trials? Has this been, you know, kind of very narrow field trials, or have you done kind of broad-based trials that, you know, really validate the technology on a kind of wider scale in the field? Well, Ben, I'd say that it is part. The herbicide program is part of our extensive field trial program. We've tested it ourselves. We've also tested it in conjunction with some of our channel partners and some third-party collaborators. If you think about where we're putting the vast majority of the Davis research team focus right now, it's on this program, the herbicide program. It's not to mean we don't have other products that we're working on, 'cause we do. If you're walking around saying, "What is Marrone Bio focusing on out of Davis?" Right now that we have the 306 product out and in the hands of the EPA, we're putting a significant amount of horsepower behind our herbicide platform. Got it. Very interesting. Well, look forward to more updates on that. Thank you for taking my questions. I'll get back in queue. Thanks, Ben. As a reminder, if you would like to ask a question, you need to press star one on your telephone. That's again, star one on your telephone. There are no further questions at this time. I will now turn the call over back to Kevin Helash, CEO, for closing comments. Thank you, operator. As we complete this year and move into the 2022 growing season, we need to deliver on four near-term tactics with long-term strategic benefits. First, we have to ensure our products are in the distribution channel and available on demand to our customers. Second, we must be opportunistic to take advantage of disruptions in the marketplace. Third, we have to build on the momentum of our seed treatment offerings globally. Fourth, we must maximize our presence on farm by leveraging our BioUnite program. Our strategy remains sound, and we have the wherewithal to execute it to the advantage of all of our stakeholders. Thank you again, everybody, and we look forward to speaking with you in the near future. This concludes today's conference call. Thank you all for participating. You may now disconnect.